ArticleJournal of gastrointestinal oncology2022
Identification of a glycolysis-related gene signature for predicting pancreatic cancer survival.
Article in Journal of gastrointestinal oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Robust and consistent biomarker candidates identification by a machine learning approach applied to pancreatic ductal adenocarcinoma metastasis.BMC medical informatics and decision making · 2024Article
- Review
- Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer.BJS open · 2023Article
- Comprehensive Analysis of Necroptosis in Pancreatic Cancer for Appealing its Implications in Prognosis, Immunotherapy, and Chemotherapy Responses.Frontiers in pharmacology · 2022Article
- Identification of a lncRNA based signature for pancreatic cancer survival to predict immune landscape and potential therapeutic drugs.Frontiers in genetics · 2022Article
- Energy metabolism disorder dictates chronic hypoxia damage in heart defect with tetralogy of fallot.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer (PC) is one of the most common malignant tumors of the digestive tract. Its clinical symptoms are obscure and atypical. It is difficult to diagnose and treat. Tumor cells mainly obtain energy through glycolysis to promote their growth. Inhibiting glycolysis can inhibit proliferation and kill tumor cells. Methods: Using bioinformatics method, we investigate the relationships between glycolysis-related genes and PC tumor samples' epidemiologic information comprehensively. Results: Different expression levels of 27 genes were identified. Using bioinformatics methods, we plotted two subgroup curves based on glycolysis-related gene expression level. Potential predictive genes were screened and their prognostic values were analyzed. Survival among high-risk group and low risk group had significant difference. Receiver operating characteristic (ROC) curve analysis indicated that area under curve (AUC) of 10 genes was greater than 0.8. These genes could be used for clinical diagnosis and prediction for PC. Two potential predictors [Kinesin Family Member 20A (KIF20A) and MET Proto-Oncogene, Receptor Tyrosine Kinase (MET)] that met the independent predictive value were selected. In univariate analysis, we screened out 3 regulators MET, protein kinase CAMP-activated catalytic subunit alpha (PRKACA) and KIF20A. According to the 3 regulatory factors, the prognostic signals of PC were constructed, by which the samples with good prognosis and poor prognosis can be clearly distinguished independently of potential confounding factors. Conclusions: Our results indicate that for PC, glycolysis -related genes could be promising therapeutic targets or prognostic indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.